Clinical evidence on the magnitude of change in growth pathway activity in relation to Tamoxifen resistance is required.

CONCLUSION: Although clinical findings regarding the molecular pathways downstream of RTKs have been thoroughly discussed in this review, further clinical studies are required in determining a consistency between preclinical and clinical findings. Discovering the best targets in preventing tumor progression requires thorough comprehension of estrogen-dependent and estrogen-independent pathways during Tamoxifen resistance development. Indeed, exploring additional clinically-proven targets would allow for better characterized treatments being available for breast cancer patients. PMID: 28786348 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28786348?dopt=Abstract

Source: Current Cancer Drug Targets - August 8, 2017 Category: Cancer & Oncology Authors: Mansouri S, Farahmand L, Teymourzadeh A, Majidzadeh-A K Tags: Curr Cancer Drug Targets Source Type: research